Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO Sells 100,000 Shares of Stock

Key Points

• George W. Lemaitre, CEO of LeMaitre Vascular, sold 100,000 shares for $9,351,000 on August 6th, reducing his ownership to 1,727,003 shares, valued at approximately $161.49 million.
• LeMaitre Vascular reported $0.60 EPS for the latest quarter, exceeding estimates, and its revenue rose 15% year-over-year to $63.15 million.
• The company declared a quarterly $0.20 dividend, with an ex-dividend date of August 21st, representing a 0.9% yield and a payout ratio of 38.83%.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) CEO George W. Lemaitre sold 100,000 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the completion of the sale, the chief executive officer owned 1,727,003 shares of the company's stock, valued at $161,492,050.53. This trade represents a 5.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

LeMaitre Vascular Stock Performance

LMAT stock traded up $0.56 during trading on Wednesday, reaching $94.94. 14,395 shares of the company's stock were exchanged, compared to its average volume of 188,926. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The firm has a market cap of $2.15 billion, a PE ratio of 46.09, a P/E/G ratio of 2.38 and a beta of 0.79. The company's fifty day moving average price is $83.82 and its 200-day moving average price is $86.52. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. The company had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. LeMaitre Vascular's revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.52 earnings per share. On average, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. LeMaitre Vascular's payout ratio is 38.83%.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently modified their holdings of the stock. F m Investments LLC raised its position in shares of LeMaitre Vascular by 2.8% during the second quarter. F m Investments LLC now owns 47,194 shares of the medical instruments supplier's stock worth $3,919,000 after purchasing an additional 1,294 shares during the period. Inceptionr LLC purchased a new stake in shares of LeMaitre Vascular during the 2nd quarter worth about $254,000. Advisors Asset Management Inc. raised its stake in shares of LeMaitre Vascular by 3.0% during the 2nd quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier's stock worth $341,000 after purchasing an additional 118 shares in the last quarter. Laurel Wealth Advisors LLC raised its stake in shares of LeMaitre Vascular by 8,205.6% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,495 shares of the medical instruments supplier's stock worth $124,000 after purchasing an additional 1,477 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of LeMaitre Vascular during the 2nd quarter worth about $635,000. 84.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

LMAT has been the subject of a number of analyst reports. Barrington Research upgraded LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective for the company in a research report on Wednesday, August 6th. Cantor Fitzgerald boosted their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $98.00.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.